While in study of the phenethylamine compounds 3,4,5-trimethoxy-beta,beta-Dideuterophenethylamine and 3,5-Dimethoxy-4-trideuteromethoxy-Phenethylamine I became very interested in replacing hydrogen with heavy hydrogen in psychedelic molecules, so when I saw an article covering this same switching of hydrogen isotopes in the dimethyltryptamine molecule I was instantly intrigued.

-EG

http://www.sciencedirect...cle/pii/0091305782902404

A comparison of the behavioral effects of proteo- and deutero-N, N-dimethyltryptamine
Author(s) listed are: John M. Beaton, Steven A. Barker

Abstract:
The behavioral effects of N,N-dimethyltryptamine (DMT) and α, α, β, β-tetradeutero-N,N-dimethyltryptamine (D4DMT) at dose levels of 2.5 and 5.0 mg/kg were examined in rats on a food reinforced schedule. The D4DMT was observed to produce a significantly greater disruption of behavior, have a longer duration of action and a shorter time to onset than DMT. This potentiation, apparently due to the kinetic isotope effect, suggests that DMT is significantly metabolized and deactivated by deamination at the α-position

what does it all mean?!

It means in which the way DMT is broken down.
Interesting study. COuld it also suggest that it may be a molecule that if taken by humans may be a longer lasting DMT?
Would this also mean it could be orally active without an MAOI?

From what I can glean from the research paper α, α, β, β-tetradeutero-N,N-dimethyltryptamine (D4DMT) does in fact produce intensified effects of a longer duration than proteo-DMT (n,n-dimethyltryptamine) due to how the body metabolizes heavy hydrogen.

In the phenethylamine world 3,5-dimethoxy-4-Trideuteromethoxy-Phenethylamine (4-d) and 3,4,5-trimethoxy-ß,ß-dideutero-Phenethylamine (ß-D) are considered legally distinct from 3,4,5-trimethoxyphenethylamine, even though the difference is only between isotopes of hydrogen. Perhaps this compound (α, α, β, β-tetradeutero-N,N-dimethyltryptamine (D4DMT)) would fall through the same legal cracks, so long as it was not offered for human consumption...

I'm not sure that swapping out hydrogen for deuterium would affect the need for an MAOI though, but if there is something I missed that would lead you to believe this would be the case I would love to hear it, as I often overlook things at times when going over dense research papers.

I'm now very interested in α, α, β, β-tetradeutero-N,N-dimethyltryptamine (D4DMT), if anyone has any more information regarding this compound I would love to see it!

Thanks,

-EG

Got a source for that? I feel like if that were true, it would open us up to a whole new world of designer drugs.

No, I don't have a source for that information other than I've gone over the federal analogue act thousands of times, I know the difference is minuscule, and I would not want to be the first person to end up in court over such matters, but as a chemist you would admit that 3,5-dimethoxy-4-Trideuteromethoxy-Phenethylamine (4-D) is chemically different from 3,4,5-trimethoxyphenethylamine, correct? Deuterium has a proton in its nucleus that protium does not, making them chemically different, So I'm sure it would come down to your lawyer trying to convince the court that this was the case.

3,5-dimethoxy-4-Trideuteromethoxy-Phenethylamine (4-D), 3,4,5-trimethoxy-ß,ß-dideutero-Phenethylamine (ß-D) and α, α, β, β-tetradeutero-N,N-dimethyltryptamine (D4DMT) are not covered or mentioned by any law. In addition I can't find record of any court cases involving hydrogen isotopes in the legality of a compound and so long as the compound was not offered for human consumption I don't think the analogue act would be a problem.

I'm not sure as to why deuterium homologues have not made an appearance in the research chemical scene,all though when I was speaking of "legally distinct" I was speaking in terms of scientific research and not so much in terms of the "RC" market place.

-EG